On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Vision Strengthens Company’s Position in Emerging Wellness Trend

  • Psychedelics pose potential as effective treatments for mental-health issues such as depression, anxiety, and substance abuse
  • Well+Good says psychedelics “poised to change the course of mental health treatment”
  • Cybin working to combine novel psychedelic molecules with controllable drug-delivery systems through proprietary deuterated process

A USA Today article is touting psychedelics as the next big thing in mental health treatment (https://nnw.fm/icXVf). This forecast aligns perfectly with what Cybin (NEO: CYBN) (NYSE American: CYBN) has been working toward since the company started: a strategic psychedelics to therapeutics model that will transform the mental health space. 

“If you haven’t heard about psychedelics being used as a treatment for mental health disorders, this year may change that,” the article stated. “While this type of treatment won’t be accessible to everyone in 2022 (and will likely take a while to become widespread), experts say you should expect to hear much more about this emerging wellness trend this year and beyond.

“‘For a long time, psychedelics have been sort of frowned upon,’ says Amy Morin, psychotherapist and editor-in-chief at VeryWell Mind. ‘We thought they were more recreational drugs, but with a closer look, we’ve seen they can actually be really good treatments for things like depression, anxiety, even substance abuse issues.’”

The article noted that Dr. Matthew W. Johnson, a professor of psychiatry and behavioral sciences at Johns Hopkins and acting director of the Johns Hopkins Center of Psychedelics and Consciousness Research, has seen a gradual increase in interest around psychedelics since he began focusing on them in 2004, but he said interest now is increasing dramatically; he thinks that interest will only increase moving forward. 

“In their 2022 wellness trend forecast, Well+Good dubbed psychedelics as being ‘poised to change the course of mental health treatment,’” the article stated. “Institutions are also getting ready by opening up specialized centers to study these drugs in a mental health capacity.”

This dramatic increase bodes well for one of the leaders in the psychedelic space. On a mission to revolutionize mental health care, Cybin has developed key relationships with a network of world-class partners and internationally recognized scientists as it focuses on creating safe and effective therapeutics for patients to address a multitude of mental health issues. The company is working on turning its psychedelics to therapeutics vision into reality by engineering proprietary drug-discovery platforms, innovative drug-delivery systems, novel formulation approaches and treatment regimens for mental health disorders. 

At the core of this transformative work is Cybin’s efforts to combine novel psychedelic molecules with controllable drug-delivery systems through its proprietary deuterated process. In doing so, the company is creating patent-protected, commercially scalable drug candidates and establishing itself as a strong player in an industry projected to see significant growth.

For more information, visit the company’s website at www.Cybin.com.

NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://nnw.fm/CYBN

About NetworkNewsWire

NetworkNewsWire (“NNW”) is a financial news and content distribution company, one of 40+ brands within the InvestorBrandNetwork (“IBN”), that provides: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) enhanced press release solutions to ensure maximum impact; (4) social media distribution via IBN millions of social media followers; and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience comprising investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

NetworkNewsWire is part of the InvestorBrandNetwork

Archives

Select A Month

NetworkNewsWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Doge Coin

Dogecoin

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 212.418.1217